Did you know your On-X® Aortic Heart Valve patients can be enrolled at an activated clinical trial site?
The PROACT Xa Trial is evaluating the safety and efficacy of apixaban compared to warfarin in patients with a previously implanted On-X Aortic Valve or On-X Ascending Aortic Prosthesis (AAP).
What patients can expect from their experience:
• Randomization (1:1) to either apixaban or warfarin (INR 2-3)
• Study medication shipped straight to their home
• Monthly follow up with enrolling site (potentially virtual) for a minimum of 2 years.
• No change in frequency or method of INR monitoring (control group)
Your patients can be enrolled in the PROACT Xa trial at an enrolling PROACT Xa trial site without your site having to go through site activation or dedicating resources to the trial.
For more information, please fill out the form below, and a member of the PROACT Xa Study team will follow up with you.
Except as otherwise noted, all trademarks are owned by Artivion, Inc. or its subsidiaries. The On-X Aortic Valve is not currently approved by the FDA for use with apixaban or any other anticoagulation, except vitamin K antagonist. ELLIQUIS® is a registered trademark of the Bristol-Myers Squibb Company. Neither Artivion nor the PROACT Xa Trial are affiliated with, sponsored, or endorsed by the Bristol-Myers Squibb Company. Not all products and indications are available or approved in all markets. © 2022 Artivion, Inc. All rights reserved.